vs
EXACT SCIENCES CORP（EXAS）与Natera, Inc.（NTRA）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Natera, Inc.的1.3倍（$878.4M vs $665.5M）。Natera, Inc.净利率更高（7.1% vs -9.8%，领先16.9%）。Natera, Inc.同比增速更快（39.8% vs 23.1%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $37.8M）。过去两年Natera, Inc.的营收复合增速更高（34.5% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Natera是总部位于美国得克萨斯州奥斯汀的临床基因检测企业，主打无创游离DNA（cfDNA）检测技术，业务覆盖女性健康、肿瘤及器官健康三大核心赛道。其自研专利技术结合前沿分子生物学手段与生物信息学工具矩阵，可实现单管血液样本中低至单个分子级别的高灵敏度检测。
EXAS vs NTRA — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$665.5M
营收增速更快
NTRA
高出16.7%
23.1%
净利率更高
NTRA
高出16.9%
-9.8%
自由现金流更多
EXAS
多$82.6M
$37.8M
两年增速更快
NTRA
近两年复合增速
17.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $665.5M |
| 净利润 | $-86.0M | $47.3M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | -3.4% |
| 净利率 | -9.8% | 7.1% |
| 营收同比 | 23.1% | 39.8% |
| 净利润同比 | 90.1% | 187.9% |
| 每股收益（稀释后） | $-0.45 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASNTRA
| Q4 25 | $878.4M | $665.5M | ||
| Q3 25 | $850.7M | $592.2M | ||
| Q2 25 | $811.1M | $546.6M | ||
| Q1 25 | $706.8M | $501.8M | ||
| Q4 24 | $713.4M | $476.1M | ||
| Q3 24 | $708.7M | $439.8M | ||
| Q2 24 | $699.3M | $413.4M | ||
| Q1 24 | $637.5M | $367.7M |
净利润EXASNTRA
| Q4 25 | $-86.0M | $47.3M | ||
| Q3 25 | $-19.6M | $-87.5M | ||
| Q2 25 | $-1.2M | $-100.9M | ||
| Q1 25 | $-101.2M | $-66.9M | ||
| Q4 24 | $-864.6M | $-53.8M | ||
| Q3 24 | $-38.2M | $-31.6M | ||
| Q2 24 | $-15.8M | $-37.5M | ||
| Q1 24 | $-110.2M | $-67.6M |
毛利率EXASNTRA
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASNTRA
| Q4 25 | -9.4% | -3.4% | ||
| Q3 25 | -3.0% | -16.5% | ||
| Q2 25 | -0.3% | -20.2% | ||
| Q1 25 | -13.6% | -15.8% | ||
| Q4 24 | -122.8% | -13.6% | ||
| Q3 24 | -5.6% | -8.9% | ||
| Q2 24 | -3.8% | -10.6% | ||
| Q1 24 | -16.7% | -20.2% |
净利率EXASNTRA
| Q4 25 | -9.8% | 7.1% | ||
| Q3 25 | -2.3% | -14.8% | ||
| Q2 25 | -0.1% | -18.5% | ||
| Q1 25 | -14.3% | -13.3% | ||
| Q4 24 | -121.2% | -11.3% | ||
| Q3 24 | -5.4% | -7.2% | ||
| Q2 24 | -2.3% | -9.1% | ||
| Q1 24 | -17.3% | -18.4% |
每股收益（稀释后）EXASNTRA
| Q4 25 | $-0.45 | $0.36 | ||
| Q3 25 | $-0.10 | $-0.64 | ||
| Q2 25 | $-0.01 | $-0.74 | ||
| Q1 25 | $-0.54 | $-0.50 | ||
| Q4 24 | $-4.69 | $-0.41 | ||
| Q3 24 | $-0.21 | $-0.26 | ||
| Q2 24 | $-0.09 | $-0.30 | ||
| Q1 24 | $-0.60 | $-0.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.7B |
| 总资产 | $5.9B | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASNTRA
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | $1.0M | ||
| Q2 25 | $858.4M | $16.0M | ||
| Q1 25 | $786.2M | $17.8M | ||
| Q4 24 | $1.0B | $22.7M | ||
| Q3 24 | $1.0B | $29.5M | ||
| Q2 24 | $946.8M | $90.3M | ||
| Q1 24 | $652.1M | $69.1M |
股东权益EXASNTRA
| Q4 25 | $2.4B | $1.7B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $3.2B | $878.5M | ||
| Q2 24 | $3.2B | $836.5M | ||
| Q1 24 | $3.1B | $794.1M |
总资产EXASNTRA
| Q4 25 | $5.9B | $2.4B | ||
| Q3 25 | $5.9B | $1.8B | ||
| Q2 25 | $5.8B | $1.8B | ||
| Q1 25 | $5.7B | $1.7B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $6.7B | $1.6B | ||
| Q2 24 | $6.7B | $1.5B | ||
| Q1 24 | $6.4B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $73.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $37.8M |
| 自由现金流率自由现金流/营收 | 13.7% | 5.7% |
| 资本支出强度资本支出/营收 | 3.6% | 5.4% |
| 现金转化率经营现金流/净利润 | — | 1.56× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $109.1M |
8季度趋势，按日历期对齐
经营现金流EXASNTRA
| Q4 25 | $151.7M | $73.9M | ||
| Q3 25 | $219.9M | $59.4M | ||
| Q2 25 | $89.0M | $37.6M | ||
| Q1 25 | $30.8M | $44.5M | ||
| Q4 24 | $47.1M | $52.9M | ||
| Q3 24 | $138.7M | $51.8M | ||
| Q2 24 | $107.1M | $4.0M | ||
| Q1 24 | $-82.3M | $27.0M |
自由现金流EXASNTRA
| Q4 25 | $120.4M | $37.8M | ||
| Q3 25 | $190.0M | $37.0M | ||
| Q2 25 | $46.7M | $11.7M | ||
| Q1 25 | $-365.0K | $22.6M | ||
| Q4 24 | $10.7M | $34.8M | ||
| Q3 24 | $112.6M | $35.5M | ||
| Q2 24 | $71.2M | $-7.7M | ||
| Q1 24 | $-120.0M | $6.7M |
自由现金流率EXASNTRA
| Q4 25 | 13.7% | 5.7% | ||
| Q3 25 | 22.3% | 6.2% | ||
| Q2 25 | 5.8% | 2.1% | ||
| Q1 25 | -0.1% | 4.5% | ||
| Q4 24 | 1.5% | 7.3% | ||
| Q3 24 | 15.9% | 8.1% | ||
| Q2 24 | 10.2% | -1.9% | ||
| Q1 24 | -18.8% | 1.8% |
资本支出强度EXASNTRA
| Q4 25 | 3.6% | 5.4% | ||
| Q3 25 | 3.5% | 3.8% | ||
| Q2 25 | 5.2% | 4.7% | ||
| Q1 25 | 4.4% | 4.3% | ||
| Q4 24 | 5.1% | 3.8% | ||
| Q3 24 | 3.7% | 3.7% | ||
| Q2 24 | 5.1% | 2.8% | ||
| Q1 24 | 5.9% | 5.5% |
现金转化率EXASNTRA
| Q4 25 | — | 1.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
NTRA
暂无分部数据
